Cargando…
COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants
The coronavirus disease 2019 (COVID-19) pandemic is one of the most consequential global health crises in over a century. Since its discovery in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate into different variants and sublineages, rendering previously potent...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Immunologists
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166656/ https://www.ncbi.nlm.nih.gov/pubmed/37179752 http://dx.doi.org/10.4110/in.2023.23.e13 |
_version_ | 1785038488023859200 |
---|---|
author | Padasas, Bill Thaddeus Españo, Erica Kim, Sang-Hyun Song, Youngcheon Lee, Chong-Kil Kim, Jeong-Ki |
author_facet | Padasas, Bill Thaddeus Españo, Erica Kim, Sang-Hyun Song, Youngcheon Lee, Chong-Kil Kim, Jeong-Ki |
author_sort | Padasas, Bill Thaddeus |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic is one of the most consequential global health crises in over a century. Since its discovery in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate into different variants and sublineages, rendering previously potent treatments and vaccines ineffective. With significant strides in clinical and pharmaceutical research, different therapeutic strategies continue to be developed. The currently available treatments can be broadly classified based on their potential targets and molecular mechanisms. Antiviral agents function by disrupting different stages of SARS-CoV-2 infection, while immune-based treatments mainly act on the human inflammatory response responsible for disease severity. In this review, we discuss some of the current treatments for COVID-19, their mode of actions, and their efficacy against variants of concern. This review highlights the need to constantly evaluate COVID-19 treatment strategies to protect high risk populations and fill in the gaps left by vaccination. |
format | Online Article Text |
id | pubmed-10166656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Korean Association of Immunologists |
record_format | MEDLINE/PubMed |
spelling | pubmed-101666562023-05-10 COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants Padasas, Bill Thaddeus Españo, Erica Kim, Sang-Hyun Song, Youngcheon Lee, Chong-Kil Kim, Jeong-Ki Immune Netw Review Article The coronavirus disease 2019 (COVID-19) pandemic is one of the most consequential global health crises in over a century. Since its discovery in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate into different variants and sublineages, rendering previously potent treatments and vaccines ineffective. With significant strides in clinical and pharmaceutical research, different therapeutic strategies continue to be developed. The currently available treatments can be broadly classified based on their potential targets and molecular mechanisms. Antiviral agents function by disrupting different stages of SARS-CoV-2 infection, while immune-based treatments mainly act on the human inflammatory response responsible for disease severity. In this review, we discuss some of the current treatments for COVID-19, their mode of actions, and their efficacy against variants of concern. This review highlights the need to constantly evaluate COVID-19 treatment strategies to protect high risk populations and fill in the gaps left by vaccination. The Korean Association of Immunologists 2023-03-23 /pmc/articles/PMC10166656/ /pubmed/37179752 http://dx.doi.org/10.4110/in.2023.23.e13 Text en Copyright © 2023. The Korean Association of Immunologists https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Padasas, Bill Thaddeus Españo, Erica Kim, Sang-Hyun Song, Youngcheon Lee, Chong-Kil Kim, Jeong-Ki COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants |
title | COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants |
title_full | COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants |
title_fullStr | COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants |
title_full_unstemmed | COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants |
title_short | COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants |
title_sort | covid-19 therapeutics: an update on effective treatments against infection with sars-cov-2 variants |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166656/ https://www.ncbi.nlm.nih.gov/pubmed/37179752 http://dx.doi.org/10.4110/in.2023.23.e13 |
work_keys_str_mv | AT padasasbillthaddeus covid19therapeuticsanupdateoneffectivetreatmentsagainstinfectionwithsarscov2variants AT espanoerica covid19therapeuticsanupdateoneffectivetreatmentsagainstinfectionwithsarscov2variants AT kimsanghyun covid19therapeuticsanupdateoneffectivetreatmentsagainstinfectionwithsarscov2variants AT songyoungcheon covid19therapeuticsanupdateoneffectivetreatmentsagainstinfectionwithsarscov2variants AT leechongkil covid19therapeuticsanupdateoneffectivetreatmentsagainstinfectionwithsarscov2variants AT kimjeongki covid19therapeuticsanupdateoneffectivetreatmentsagainstinfectionwithsarscov2variants |